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CHAPTER 2

The lmmune System
Betty Bierut Gallucci,

Donna McCarthy,

Modern biotherapy has been in use for sorne
30 years. The first types of biotherapy were
nonspecific stimulators of the immune response, but advances in genetic engineering
are allowing the mass production of pure biological products which are now being tested
as pharmaceutical agents. Biotherapy connotes the administration of products (1) that
are coded by the mammalian genome; (2) that
modify the expression of mammalian genes;
or (3) that stimulate the immune system. In
this chapter the discussion of the immune system will be limited primarily to topics relevant
to cancer or autoimmune diseases.
Because understanding the new biological
agents requires an understanding of both the
immune response and the molecular basis of
oncogenesis, this chapter first presents a summary of the structure and function of the immune system. Following a discussion of immune responses, and the cells involved in
these responses, will be a discussion on the
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current concepts of oncogenesis, particularly
oncogenes and growth factors. Because research efforts are beginning to identify many
biological proteins as having a role in autoimmune and other diseases, a brief introduction
to autoimmune diseases is also included at the
end of the chapter.

THE IMMUNE SYSTEM
Overview of
the lmmune Response
The immune system is a complex, dynamic
system which evolved to protect the individual against pathogenic organisms (Figure 2.1).
In addition to recognizing and destroying foreign substances or antigens, immune responses can also destroy altered and malignant cells. This latter function of the immune
system is called immune surveillance. The
destruction of microorganisms and the de15
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Figure 2.1 The humoral branch and cell-mediated branches of the immune system . The humoral
response involves interaction of B lymphocytes with antigen and their differentiation into antibodysecreting plasma cells. The secreted antibody binds to the antigen and facilitates its clearance from
the body. The cell-mediated response involves various subpopulations of T lymphocytes that
recognize antigen p,resented on self-cells. TH-cells respond to antigen with the production of
lymphokines and cytotoxic T lymphocytes (CTL) mediate killing of cells that have been altered by
antigen (e.g., virus-infected cells).
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Source: IMMUNOLOGY by )anis Kuby. Copyright (e) 1992 by W.H. Freeman and Company. Reprinted with permission.
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Table 2.1

Functions of the lmmune System

Protection

Recognition and destruction of
pathogenic microorganisms
Destructio.p of malignant cells
Destruction of worn and damaged
ce lis
Recognition of self components
Augmentation and depression of
immune responses

Surveillance
Homeostasis
Tolerance
Regulation

struction of tumor cells involve the same immunologic mechanisms. The mechanisms
used to fight viral diseases are particularly
important in immune responses to tumors.
See Table 2.1 for a summary of functions of
the immune system.
lmmune responses involve a number of
different cell types and their products. Because it is impossible to discuss or study all
the responses at the same time, they are divided into two types, innate and adaptive.
Innate immunity is also called natural or nonspecific immunity and includes the inflammatory response. Adaptive immunity is also
k.nown as specific or acquired immunity. For a
review of innate and adaptive immune responses, see Table 2.2.
Innate immunity is the first line of defense
against pathogenic organisms; adaptive immunity involves the recognition of specific
foreign determinants and a memory response.
To recognize and destroy what is foreign also
implies that the immune system must be able
to tolerate self, that is, to tolerate its own cells
and their products. If the molecules on the
microorganism or tumor cell are recognized
as foreign (nonself or altered self) and stimulate a specific immune response, they are
called antigens. The small area of the antigen
that binds to the lymphocyte receptor is the
antigenic determinant or epitope.
The cells and products of innate and
adaptive immune responses act in concert and
are aH responsible for resistance to pathogens
and surveillance. For instance, the first line of
defense against pathogenic organisms (e.g.
Pseudomonas) are mechanical barriers such as
intact skin and mucous membranes. If these
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physicaJ barriers are breached, an inflammatory response attempts to limit the colonization of the microbe. The acute inflammatory
response involves the physiological processes
of capillary dilatation, exudation of fluid and
plasma protein into the tissues, and accumulation of neutrophils at the site of infection.
These responses are manifested clinica11y as
the five cardinal signs of inflammation: heat,
redness, swelling, pain, and loss of function.
The invading organism is then killed through
phagocytosis by neutrophils or soluble chemical factors generated during the inflammatory
response (Figure 2.2). The influx of neutrophils is replaced by monocytes, which continue to migrate to the inflammed area. The
activation of monocytes is the bridge between
innate and adaptive immunity. Monocytes are
capable of processing the antigen they phagocytize and presenting it to other white
blood cells involved in adaptive or specific
immunity.
Thus, if this innate response fails and the
organism colonizes the body, the adaptive immune system is stimulated and responds. The
specific immune response on the next exposure to the same antigen will be heightened
and more rapid. This secondary response is
called memory or anamnestic response.
Generally speaking, the white blood cells
are responsible for immune responses; granulocytes (neutrophils, eosinophils, and basophils), monocytes and their tissue counterparts
macrophages are involved in innate immunity,
whereas lymphocytes are responsible for specific immun~ responses. Lymphocytes have
two different ways of recognizing antigenic
determinants. The first is by antibodies located
on the membrane of B lymphocytes and the
second is by T-lymphocyte (or T-cell) receptors. For the T-cell receptors to recognize the
antigenic determinants the antigen must be
present along with self molecules or major histocompatibility (MHC) molecules. Typically,
both the innate and adaptive systems (both B
and T lymphocytes) are needed to effect a
response sufficient to contain and eliminate
pathogens.
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Table 2.2

Features of innate and adaptive immunity

System
lnnate lmmunity

Adaptive lmmunity

Hallmarks
Primary line of defense
Non-specific
·No memory

Secondary line of defense
Specificity
Memory

Features and Functions
Mechanical Barriers
lntact Skin
Mucous Membranes
Chemical Barriers
lnflammatory response
Fever
Phagocytic Cells
Soluble Factors
Protects against pathogens
Lymphocytes
T-cells: Provide cell mediated
immunity
Primarily protects against intracellular
organisms, immune surveillance,
responsible for rejection of transplanted
organs and modulation of immune
response
B-cells: Provide humoral immunity
Primarily protects against viruses and
bacteria

ANTIGENS
The majar function of the immune system is to
distinguish between self molecules and nonself or altered-self molecules. Molecules that
induce a specific immune response are called
immunogens. AJI immunogens are also antigens. Allergens are antigens that induce allergic responses. The epitope or antigenic determinant is that specific part of an antigen,
allergen, or immunogen that binds directly
with the immunoglobulin or T-cell receptor.
For example, an antigenic protein may consist
of hundreds of amino acids, but only six or
seven of these bind directly with an immunoglobulin. The binding area of the antigen is
the epitope. Tolergens are molecules that induce a state of immunologic unresponsiveness. Most times antigens are exogenous molecules such as bacteria! or viral proteins.
Rarely, immune responses are generated to
self molecules, that is autoantigens or autologous antigens, resulting in serious pathologic states caBed autoimmune diseases. Alloantigens are endogenous molecules that

distinguish one individual from another individual of the same species. The A, B, and O
blood-type molecules and the histocompatibility antigens are examples of alloantigens. A
bone marrow transplant between siblings is
caBed an allogeneic transplant.
The distinction between self molecules
and foreign molecules is a learned response.
Exposure of the immune system to molecules
in utero will generate tolerance to these molecules: the immune system will not respond to
these molecules, rather they will be considered self molecules (self antigens). The greater
the difference between self molecules and exogenous or foreign molecules, the more likely
it is that an immune response will be generated. Also, the greater the evolutionary divergence between two species, the greater the
likelihood that an immune reaction will occur.
In humans, for instance, an immune response
to avian albumin is more likely than a response to primate albumin. There are, however, sorne proteins that are phylogenetically
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Figure 2.2 The inflammatory response. A bacteria! infection causes tissue damage with release of
various vasoactive and chemotactic factors. These factors induce increased blood flow to the area,
increased capillary permeability, and the influx of white blood cells, including phagocytes and
lymphocytes, from the 1blood into the tissues. The serum proteins contained in the exudate have
anti-bacterial properties and the phagocyte will begin to engulf the bacteria .
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Source: IMMUNOLOGY by )anis Kuby. Copyright (e) 1992 by W.H. Freeman and Company. Reprinted with permission .

conserved, such as collagen; these proteins
will not generate immune responses even if
transplanted across species lines.
Besides the degree of foreignness, the size
and the chemical nature of the molecules will
determine if a specific immune response is
generated. In general, proteins are more efficient immunogens than other compounds;
complex carbohydrates are also good immunogens. Lipids and nucleic acids are poor immunogens unless they are bound to proteins.
A complex molecule is likely to generate an
immune response, whereas polymers composed of a single amino acid are unlikely to
generate a response. The B and T lymphocytes

will recognize different epitopes on the same
molecule. For the T cell to recognize a molecule as foreign, the molecule first must be
phagocytized and processed, and then small
segments of the molecule must be linked to
MHC molecules on the surface of the accessory cell. Molecules that resist digestion by
phagocytes are less likely to stimulate a
T-helper cell response. If the T-helper response is limited, then neither a B-cell response nor a T-cell response is likely. The
route by which the antigen is presented to the
immune system and the dosage will affect the
type and degree of immune responses. Antigens present in the mucosa are much more
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likely to generate immunoglobulin A or E
than immunoglobulin G. A systemically administered antigen is likely to produce an immunoglobulin G response. If the antigen is
administered in yery high quantities or in
very low quantities, the host may come to
tolerate the antigen.
Mitogens are molecules that can induce
nonspecific division and activation of lymphocytes; mitogens will also stimulate many
clones of lymphocytes. This contrasts with the
specific stimulation of a single lymphocyte
clone by an antigenic epitope. Mitogens are
used in laboratory situations to test the functional ability of lymphocytes. Sorne common
mitogens used in testing of lymphocytes are
phytohemagglutinin (PHA), concanavalin A
(Con A), and pokeweed mitogen (PWM) . Both
PHA and Con A are proteins derived from
plants and are T-cell mitogens; PWM stimulates both T and B cells. These protein mitogens are also known as lectins. Sorne bacteria!
toxins act like mitogens in that they nonspecifically stimulate multiple colonies of lymphocytes. Super antigens are very potent
T-cell mitogens and stimulate T-helper cells,
an example of a super antigen is the toxic
shock syndrome toxin. This stimulation may
lead to a massive release of cytokines and to
shock and death. The lipopolysaccharide in
bacteria! endotoxin is another example of a
super antigen.

CYTOKINES
Cytokines and lymphokines are discussed
here because these molecules are a part of a
network of mediators released in inflammatory and specific immune responses. These
compounds are produced primarily by T cells,
but they can be produced by other types of
cells such as monocytes, or their mature counterpart, macrophages. The term et;tokine describes a soluble protein produced by cells,
and includes polypeptide molecules such as
interleukins, lymphokines, monokines, interferons, tumor necrosis factor, and transforming growth factor. They are biologically very

active, have short half lives, and are functional
at low concentrations. Cytokines bind to
plasma membrane receptors; they affect the
growth and differentiation of white blood
cells, and regulate immune and inflammatory
responses.
Cytokines act as signals between cells and
can exert their effect in the same cell from
which they were secreted, that is, in an autocrine action. Cytokines can affect cells in the
immediate area, a paracrine action, or they
can exhibit endocrine actions, that is, on distant cells. A cytokine can have different effects
in different target cells, that is, they are
pleiotropic. Cytokines can also act in concert:
one cytokine may potentiate (or inhibit) the
action of another cytokine. This effect is
known as the cytokine cascade.
When a T-helper cell is activated by an
antigen, for instance, the cell can secrete a
variety of cytokines, which in turn actívate B
cells, NK cells, other T cells, macrophages, or
stem cells. The target cells secrete the same
cytokine or another cytokine which can either
amplify or inhibit the immune response. Often
more than one cytokine is needed for cellular
activation, and the sequence of exposure to
the cytokines may also be important. lt is best
to consider cytokines as a system or a network
in which the cytokines can act in a redundant,
synergistic, antagonistic or pleiotropic fashion . (See Figure 2.3.)
When cytokines were first studied, their
chemical structures were not known, so functional assays were developed for each one.
Each cytokine was studied and named by the
action it produced. For instance, investigators
who studied a substance that destroyed
tumor cells named it tumor necrosis factor
(or lymphotoxin). Other investigators who
studied a substance that caused weight loss
called it cachectin. When the chemical natures of these compounds were described, it
was discovered that tumor necrosis factor,
lymphotoxin, and cachectin were really the
same compound. More than one name exists
for many of the cytokines. In 1986 an intemalional system was established to try to stan-
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Figure 2.3

Examples of the cytokine attributes of pleiotropy, redundancy, synergism, and

antagonism.
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dardize the cytokine nornenclature. (See
Chapter 5.) When the DNA sequence coding
for a protein has been discovered, it is now
given an interleukin designation. The terrn interleukin Jiterally rneans " between white
cells," however, sorne of these protein molecules are rnade by, or act on, cells other than
white blood cells.
An example is interleukin-6 (See chapter
16). Previously it was called B-cell differentiation factor, B-cell stirnulation factor, hepatocyte-stimulating factor and interferon-¡32, depending on the assay used. Interleukin-6
stimulates T-cell proliferation and differentiation in addition to the production of IL-2 and
IL-2 receptors by the T-cell. Interleukin-6 also
stirnulates plasma cells to secrete immunoglobulins and hepatocytes to secrete acute phase
response proteins such as C reactive protein.
Interleukin-6 is also important in hernatopoiesis. It is produced not only by T-helper
cells but also by rnacrophages and fibroblasts.
Therefore, it acts in a pleiotropic, redundant,
and synergistic fashion. Since it can also be
manufactured by and influence cells other
than white blood cells, the term cytokine rnay
be better than interleukin.
Cytokines rnay also play a role in bidirectional cornrnunication between the neuroendocrine and irnrnune systems. For example, interferon-c:x can increase the levels of circulating
cortisol. Interleukin-2 infused in pharmacologic
doses can cause fatigue and depression. Sorne
of the cytokines induce fever by affecting the
temperature-regulating center in the hypothalamus. Thus, cytokines rnay be important for in tegrating the irnmune response within the total
person, not just within the immune systern.
Likewise, changes in the neuroendocrine systern can heighten or diminish irnmune responses. Hormones such as cortisol and the sex
hormones generally depress the immune responses, whereas growth hormone and thymosin enhance T-cell responses. This comrnunication between systems is possible because
there are receptors on the surfaces of lymphocytes and other white blood cells for hormones
such as cortisol and epinephrine, while the ner-

vous systern has receptors for cytokines such as
interferon-c:x and IL-2.

MAJOR HISTOCOMPATIBILITY
COMPLEX
Regulation of irnmune responses occurs at
many levels: by antigens, cytokines (between
cells), and the neuroendocrine system. The
ability to respond toan antigen is determined
not only by the factors listed above but also by
the genetic constitution of the individual. The
part of the genome that we know the rnost
about with respect to immune responses is
called the major histocompatibility complex
(MHC). This area was first studied in relationship to transplantation of tissue. Because the
first cells used for testing the compatibility of
tissues between individuals were lyrnphocytes, in hurnans the MHC is called the human leukocyte antigen (HLA) complex. Here
the term antigen is used, because lyrnphocytes
from one person or donar, would be foreign to
another person, or recipient, and would stimulate an immune response to the donar cells
in the recipient. Much of the research done in
this area has used rodent models. In the
rnouse, the MHC is called the H2 complex (H
for histocornpatibility and 2 for the second
erythrocyte antigen of the mouse).
The MHC or HLA genes are located on
chromosorne 6 and code for molecules on the
cell membrane needed for the presentation of
the antigen to T lyrnphocytes. These genes
also code for sorne soluble molecules, including those of the cornplement systern and
tumor necrosis factor. The MHC cornprises
about 40 to 50 genes and, although the functions of many are understood, others are not.
The HLA is further divided into class I, ll, and
III regions; the genes code for class I, II, and Ili
molecules. These MHC molecules are often
referred to as MHC antigens.
Class I genes are located at the HLA-A,
HLA-B, HLA-C, -E, -F and -G loci. The locus is
the position on the chromosorne where a gene
is positioned. The HLA genes are located on
the short arm of chromosome 6. The class I
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genes code for molecules that are present on
most nucleated cells. For a cytotoxic T cell to
recognize an antigen, the antigen must be
complexed with a MHC class I molecule. Considering that a virus can infect any cell in the
body and that the cytotoxic T cell is responsible for killing cells infected with viruses, it
makes sense that class I molecules are ubiquitous. Class I molecules are absent in sperm
and in trophoblasts. Sorne cells of the body,
such as liver cells, fibroblasts, and neurons,
express very Iow Ievels of these genes. Perhaps the reason for the success of liver transplantation and the acceptance of the fetal tissues as grafts is the Iow numbers of class I
molecules on the membranes of these cells.
Cytokines such as tumor necrosis factor and
interferons can increase (up-regulate) the expression of these genes, increasing the numbers of class I molecules on the surfaces of
these cells.
Class li molecules are found on ce lis of the
immune system: B lymphocytes, antigen-presenting cells, accessory cells, macrophages,
Langerhans cells, and dendritic cells. The major role of class II molecules involves the presentation of the antigen to T-helper cells. The
antigen is first processed, then it binds to the
class II molecule; it is this complex that binds
to and stimulates the T-helper cell. The class II
genes are Iocated at the DO, DP, DQ, DR, DV,
DX, and DZ Ioci. The class II genes are also
known as the immune response genes and
determine the leve! of response to an antigen.
Certain animal strains that tend to respond
quantitatively more to an antigen than other
strains are called high responders. The existence of high and Iow responder strains is due
to differences in the MHC class II genes. Because both class I and II molecules have sorne
structural similarity to the immunoglobulin
molecules, they are considered to belong to
the immunoglobulin superfamily.
Class III genes code for sorne of the proteins involved in the complement pathway,
tumor necrosis factor, and steroid hydroxylase enzymes. These molecules are soluble,
diverse, and have no role in presentation of
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the antigen. The class III genes lie between the
class II and class I genes on the chromosome.

Haplotypes
There are many variants or alleles of each of
the MHC genes, allowing many variants in
each of the class I and class li molecules. This
Ieads to the great diversity seen in humans
and accounts for the difficulties in transplantation among unrelated donors. The MHC
genes are tightly linked. Usually, one copy of
the entire MHC gene (a haplotype) is inherited as a unit from the mother and another
copy is inherited from the father. Twentythree different alleles are known for the HLAA Iocus of MHC class I, 49 for the HLA-B
Iocus, and eight for the HLA-C Iocus. If there
are 50 genes in the MHC and there are many
variants of these genes; it is easy to see why it
is difficult to match for histocompatibility.
Theoretically, the number of possible MHC
genotypes in the human population would be
the number of alleles for each gene multiplied
by every other possibility, i.e. 23(A) x 49(B) x
8(C) and so on for the 50 genes. In actuality,
the total number of possibilities is Iess than
the theory predicts because certain of these
genes are tightly linked to each other making
their recombination with other genes highly
unlikely. Certain haplotypes are found more
frequently than would be expected, so that in
isolated populations a greater frequency of
certain alleles of the MHC wiii be found. Because of the. tight linkage, there is one chance
in four that siblings will share the same hapIotypes. In an individual cell both the maternal and paternal genes are expressed, that is,
the genes are codominant.

TISSUES ANO CELLS OF THE
IMMUNE SYSTEM
The Lymphoid System
The cells responsible for the immune response
are organized into tissues and organs collectively known as the Iymphoid system. Lym-
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phoid tissue can be designated as primary or
secondary. The primary organs include the
bone marrow and the thymus, and are the
sites where lymphpcytes develop and mature.
Secondary lymphoid organs include the
lymph nades, lymph vessels, spleen, tonsils,
and unencapsulated lymphoid tissue lining
the respiratory, alimentary and genito-urinary
tract. Lymphocytes are stored and activated in
the secondary organs. Lymph nades are
chains of encapsulated lymphoid tissue housing B- and T-lymphocytes. They are found
throughout the body and are located primarily at the junctions of lymphatic vessels, a
network that drains and filters tissue fluid . In
sum, lymph nades filter material draining
from body tissues, the spleen fil ters antigens
in the blood, and the unencapsulated lymph
tissue monitor mucosa! surfaces.

Cells of the lmmune System
The white blood cells (granulocytes, monocytes, lymphocytes) responsible for immune
responses are derived from bone marrow
stem cells in children and adults and the yolk
sack, spleen, and liver in the fetus. The stem
cells are pluripotent, that is, capable of producing all the formed elements of the blood,
including erythrocytes (red blood cells) and
platelets. This process of differentiation or
maturation is called hematopoiesis. Numerous growth and differentiation factors that
support hematopoiesis have been identified.
(See chapter 6.)
Many of the hematopoietic growth factors
were identified by culturing bone marrow
stem cells in vitro. Since each cluster of cells
that grew in culture was derived from a single
cell, these growth factors were called colonystimulating factors. There are four main types
of colony-stimulating tactors: multilineage
colony-stimulating factor, also called interleukin-3 (IL-3), granulocyte-macrophage colonystimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and macrophage colony-stimulating factor (M-CSF).
Other cytokines secreted by T-helper lympho-

cytes and macrophages that support hematopoiesis include such factors as interleukins1, -4, - 5, -7, -8, and -9 (IL-1, IL-4, IL- 5, IL-7,
IL-8 and IL-9). Different growth factors are
necessary at different stages of maturation.
Multilineage colony-stimulating factor is important early in the differentiation of the myeloid line of blood cells (erythrocytes, monocytes, and granulocytes), whereas G-CSF is
important in a later stage of differentiation of
the neutrophil line. (See Figure 2.4.)
Granulocytes
Neutrophils, or polymorphonuclear leukocytes, are important early in the inflammatory
process and in acute infections. They are the
most numerous of all the leukocytes, accounting for approximately 50% to 70% of circulating white blood cells. Neutrophils migrate
from the blood stream into the tissue, where
they phagocytize pathogens and cellular debris. The ability of these cells to recognize
what is antigen (and should be destroyed) is
poorly understood but is thought to involve
the chemical structure of the antigen. For example, the cell wall of sorne bacteria contain
complex polysaccharides that are not seen in
the cell wall of humans. Antibodies, produced
by B lymphocytes, may bind to the antigen
and mark it for destruction by neutrophils or
monocytes. Other circulating proteins known
as opsonins may bind to the antigen, also
marking it for phagocytosis by neutrophils or
monocytes. Basophils contain granules, and
have mediators such as histamine, which are
important in allergic reactions. In tissues, cells
similar to basophils are called mast cells. Eosinophils are phagocytes and play a role in
immune responses to parasitic worms. They
are present in small numbers in blood: they
constitute about 1% to 3% of circulating white
blood cells.
Monocytes and the Mononuclear
Phagocyte System
Monocytes are large phagocytic cells that
comprise approximately 3% to 7% of the circu-
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Figure 2.4
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lating white blood cells. They are present late
in the inflammatory process and in chronic
infections. Tissue monocytes (also called macrophages), when present along with lymphocytes, are often designated as a monocytic infiltrate on histologic examination. Macrophages contain many granules and lysosomes
and are very effective in removing cellular
debris, which is why they are often called the
"mop up troops." Many tissues contain resident macrophages, which are called different
names in different tissues. For instance, macrophages in the liver are called Kupffer cells;
in the skin, Langerhans cells; and in the brain,
glial cells. This system of macrophages has

been renamed the mononuclear phagocytk
system; it was previously termed the reticuloendothelial system.
Macrophages are not only important in
innate responses, but also they play a vital
role in adaptive immune responses. Macrophages are often involved in the first stage of
processing antigens and presenting them to
lymphocyte populations. Foreign microorganisms are phagocytized by the macrophage
and then digested in the phagosomes. Parts of
the digested foreign molecule are further processed inside the cytoplasm; these eventually
bind to the macrophage cell-surface proteins
and are expressed on the cell surface. The

26

Biotherapy: Principies and Foundations

antigen, in combination with these cell-surface
proteins or class II MHC markers, are presented to the lymphocyte. The lymphocyte
specific for that antigen then binds to the antigenic determinant" and is activated. The cells
responsible for processing antigens are also
known as antigen processing cells or accessory cells. Macrophages can also bind antibodies on their cell surfaces, which will permit
them to more readily phagocytize specific antigens. When the antigen and antibody bind,
the macrophage is thus activated and becomes
more efficient in destroying invading microorganisms.
Lymphocytes
Lymphocytes constitute about 20% to 40% of
circulating white blood cells and are responsible for the recognition of antigens and induction of adaptive (specific) immune responses.
Lymphocytes also reside in lymphatic tissues
throughout the body, which include such
structures as the tonsils, adenoids, lymph
nades, thymus, spleen, appendix, Peyer's
patches, and bone marrow. The lymphatic tissue underlining the mucous membranes,
MALT (mucosa-associated lymphatic tissue),
BALT (bronchus-associated lymphatic tissue),
and GALT (gut-associated lymphatic tissue),
is not encapsulated, nor is itas well organized
as that of the lymph nades. In the mucosa,
these loase dusters of lymphocytes can interact with antigens at the lumenal surface and
prevent antigens from gaining access to the
systemic circulation.
Lymphocytes recirculate throughout the
body by leaving the vasculature or lymphatic
tissue and infiltrating tissues. They then reenter the circulation via lymphatic vessels and
once again take up residence in the lymphatic
tissue. Lymphocytes possess adhesion and
homing receptors on their surfaces, which
permit them to bind to the vascular endothelial cells in general and endothelial cells in
specific tissues. The venule endothelial cells
possess vascular adhesion molecules which in
turn bind with the lymphocyte homing recep-

tors. This recirculation of lymphocytes ensures that antigens come in contact with responsive lymphocytes. lt is thought that only
1 in 1,000 to 1 in 100,000 lymphocytes have the
ability to respond to a specific antigen.
Although al! lymphocytes look similar in
a routine blood smear, there are subpopulations. The current method to distinguish cell
populations and subpopulations is by staining
cell surface molecules with monoclonal antibodies linked to fluorescent dyes. Monoclonal
antibodies are highly specific antibodies produced from a single clone of cells. (See Chapter 7.) These surface molecules are called cluster of differentiation (CD) antigens (or CD
markers). The monoclonal antibodies that are
attached to the cell markers and the markers
themselves have been assigned CD numbers
by an international workshop. Of the three
majar populations of lymphocytes, T lymphocytes, B lymphocytes, and natural killer (NK)
cells, T and B lymphocytes are responsible for
specific immune responses and natural killer
cells are involved in innate immune reactions
to viruses and tumors cells. Although CDS is
a marker for both T and B cells, COl, CD3,
and CD7 are markers only for T cells; CD21,
CD22, CD37, and CD40 are a few of the
antigens associated with B cells. CD56 is a
marker for NK cells. In many cases the function of the cell surface molecule is known.
For instance CD21 on B cells is a receptor for
a complement molecule and is also the Epstein-Barr virus receptor.
8 Lymphocytes In humans, the stem cells for
B lymphocytes are located in the bone marrow. In the bird, however, B cells mature in a
Iymphoid organ called the bursa of Fabricius,
which is similar in structure to the human
appendix. Since it was in the bird that the
function of B cells was first determined, now
al! lymphocytes that secrete antibodies are
called B cells. The molecules on the surface of
B cells that are responsible for binding antigen
are called membrane-bound immunoglobulins (lg) . On the surface of any one B cell, all
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the immunoglobulin receptors are identical in
structure and thus bind to only one particular
antigen. The most mature form of the B lymphocyte is the plasma' cell, whose function is
to secrete immunoglobulins (i.e., antibodies).
All the daughter cells derived from a single B
cell will produce the same antibody, therefore
the name monoclonal antibody is given to the
immunoglobulin secreted from a particular
clone of B cells. Antibodies or immunoglobulins are found in the plasma, the fluid portian of blood; therefore the historical name
associated with the specific immunity produced by B cells is humoral immunity. Other
names associated with B cell immunity are
antibody-mediated immunity and immediate
hypersensitivity reactions. (See Figure 2.5).
The B lymphocytes constitute approximately S% to 15% of circulating lymphocytes;
plasma cells, however, do not circulate but
remain fixed in the lymphoid tissue. Collections of B cells in lymphoid tissue stain intensely. These collections of B cells are called
primary and secondary follicles (or germinal
centers). Because B cells predominate, the collections are also called T-independent areas in
the lymph nades. Small amounts of T cells and
macrophages are present even in the T-independent areas. Many B cells require the presence of T cells and accessory cells to manufacture antibodies.
T Lymphocytes T lymphocytes are derived
from a population of lymphocytes that mature
in the thymus. Lymphocyte stem cells migrate
from the bone marrow to the thymus in the
fetus and in childhood. In the thymus, lymphocyte populations that will react to self molecules (or self antigens) are eliminated and the
other T cells differentiate. As the T cells mature, they leave the thymus and migrate to the
lymphatic tissue, populating the areas surrounding the germinal centers, paracortical
areas. The T lymphocytes constitute about
70% to 80% of circulating lymphocytes. They
are responsible for immune reactions such as
graft rejection, graft-versus-host disease, con-
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tact skin sensitivity, and delayed hypersensitivity reactions.
Much of what we know about the T cells
was discovered in the nude (hairless) mouse.
Because these mice are born without a thymus, they are unable to reject transplanted
tissue even if the tissue is from another species. Nude mice are often used as incubators
of human tumor cell lines because they are
unable to reject the foreign tissue. The T lymphocytes are also important regulators of immune responses. As with all physiological responses, regulation of the immune response is
necessary to either stimulate or inhibit the reactions.
Like B cells, T cells can recognize and bind
to specific antigens. lt is the T-cell receptor
that binds the antigen. There are two types of
T-cell receptors, TCRl and TCR2; anda particular T cell possesses only one of these types.
In the T-cell membrane, the T-cell receptor is
linked to a molecule called CD3. The T cell can
recognize a foreign antigen only if it is linked
to a self molecule (also known as MHC antigens) on the surface of another cell. The T-cell
immune responses are particularly effective in
eliminating intracellular pathogens, for instance, cells that are infected with a virus and
express viral antigens on their cell surfaces.
This is in contrast to the immunoglobulins,
which can bind to soluble antigens and help
eliminate extracellular microorganisms.
The T-lymphocyte population can be further divided into severa! subpopulations that
can be distinguished by the CD4 and CD8
markers. The T4 cells (which express CD4
markers) are called helper/inducer T-cells.
For the T-helper cells to recognize an antigen,
the antigen must be present on another cell
that has MHC class H molecules. Thus,
T-helper lymphocytes are called class 11restricted cells. These cells secrete cytokines
called lymphokines, sorne of which stimulate
the growth and differentiation of B lymphocytes and others of which activate macrophages. The T-helper lymphocytes also induce
the generation of cytotoxic T lymphocytes. lt

28

Biotherapy: Principies and Foundations

Figure 2.5 Differentiation and maturation of T lymphocytes and B lymphocytes. T cells develop in
the thymus from cells that originate in the bone marrow. Mature T cells interact with antigen in
peripheral tissues and then divide and differentiate into effector T cells. B cells develop in the bone
marrow in humans. and when mature migra te to peripheral tissues. When stimulated with antigen,
they differentiate into antibody-secreting plasma cells and memory cells.
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should be noted that the human immunodeficiency virus (HIV) appears to bind to the CD4
molecule on T-helper lymphocytes. The selective infection, and ultrmate de mise of T-helper
lymphocytes, explains the amazing severity
with which the HIV virus disables the immune system.
The cytotoxic T cells, on the other hand,
express CDB markers and can recognize only
antigens associated with MHC class 1 molecules, that is, they are MHC class 1-restricted.
Cytotoxic T cells can recognize and bind to
cells with altered self antigens or viral antigens bound to MHC class 1 molecules. They
release a variety of mediators that cause the
altered cell to lyse, or kili, the target cell. The
suppressor T-cells al so have the CDB markers
on their surfaces. They inhibit, or downregulate, both T and B cell immune reactions
and are responsible for tolerance to self. Various monoclonal antibodies are now being developed that would distinguish the cytotoxic
T from the T-suppressor subsets and the
helper-inducer from the suppressor-inducer
subsets. Both helper and suppressor T lymphocytes are necessary for maintaining an appropriate leve! of immune responsiveness.
(See Figure 2.5.)
Other lymphocytes that
are neither B or T lymphocytes include null, natural killer, killer, lymphokine activated killer
(LAK), and tumor infiltrating lymphocytes (TIL)
cells. Null cells are lymphocytes that lack both T
and B cell markers; whereas the NK cells and
other killer cells carry sorne T-cell markers or
both T-cell and macrophage markers. At one
time it was believed that nuU, NI<, and other
killer cells were separate and distinct lymphocyte
lineages. We now know, however, that as lymphocytes differentiate or become activated, they
lose certain markers and gain others. Thus, sorne
subsets may be simply more mature (differentiated) forms of the same line of lymphocytes. Although the exact lineage has not been worked out
for al! the subsets of lymphocytes, they can be
distinguished from each other by their functional
properties and cytoplasmic characteristics.
Other Lymphocytes
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Natural killer cells are large lymphocytes
that possess membrane-bound granules that
contain hydrolytic enzymes. They constitute
about 15% of the circulating lymphocytes.
These large granular lymphocytes can in culture spontaneously destroy malignant cell
lines. Functionally, NK cells can recognize and
destroy tumor cells without having prior exposure and are not MHC restricted. Natural
killer cells can destroy tumor cells by direct
contact and release of perforins, molecules
that form doughnut-shaped pores in the target cell membrane. The other process by
which killer cells destroy target cells is by
antibody-dependent cell-mediated cytotoxicity (ADCC). In the process, killer cells bind
antibodies to their surfaces. When these antibodies bind to the tumor cell antigens, cytotoxic enzymes are released, resulting in tumor
cell destruction. In laboratory studies, NK
cells have potent antitumor activity early in
tumor development and prevent the metastatic spread of tumors.
Recent biotherapy clinical trials have
identified two other subsets of lymphocytes.
When lymphocytes are incubated with large
concentrations of the lymphokine interleukin2 (IL- 2), they are able to lyse tumor cell lines
and fresh tumor ce lis. These Iymphokine activated killer (LAK) cells are able to destroy
tumor cells more efficiently than normal lymphocytes. Tumor-infiltrating Iymphocytes
(TIL), are isolated from excised tumors. These
lymphocytes, when grown in culture with
lower concentrates of IL-2 than LAK cells,
appear to be more specific for killing tumor
cells derived from the host. Natural killer,
LAK, and TIL cells may al! be related to each
other and derived from the same lymphocyte
cell line. Only future studies will determine
this. See Table 2.3 for a summary of immune
cell functions .

SPECIFIC IMMUNE RESPONSES
The type and the strength of an immune response is dependent on the properties of the
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Table 2.3

lmmune system cells and their functions

lnnate lmmunity
Neutrophils
Basophils
Eosinophils
Monocytes
Natural Killer Cells

Phagocytosis; present in acute infections
Release of local mediators (histamine); allergic reactions
Present in allergic reactions
Phagocytosis; present in chronic infections
Natural immunity to viruses and tumors; expansion of T-cell responses

Adaptive lmmunity
Lymphocytes
B lymphocytes
Plasma Cells
Memory Cell
T lymphocytes
T helper
T cytotoxic
T suppressor
T memory

Membrane bound lg binds to antigen
Most mature form of B cell, produces lg
Responsible for memory effect
Membrane bound receptors bind to antigen
lnitiation of immune response, secretion of lymphokines, assist B cell production
of antibody
Kills cells by lysis
Decreases the immune response of other T- or B-cells
Responsible for memory effect

antigen, which lymphocyte populations are
activated, and the genetic and hormonal
characteristics of the individual. The way the
antigen is recognized will determine which
types of immune responses occur. Each individual produces both B-cell and T-cell responses as well as the innate immune responses to an antigen. In fact, all these
responses are interlinked; al1 are constituents
of an integrated defense system. The responses to a microorganism colonizing the
host can not always be predicted, however;
even the simplest of microbes are very complex and have many molecules that can activate immune cells. Nor is there any guarantee that the immune responses will be beneficia!. Indeed, if one type of immune response
prevents another more effective response,
then the effect is detrimental.

8-Cell Responses
Activation of 8 lymphocytes
Resting B lymphocytes are in the G0 (resting)
phase of the cell cycle. When a lymphocyte is
activated, it enters the cell cycle and moves
through the G1, S, G2 , and division phases. In
the S phase of the cell cycle, DNA is synthesized, whereas in the G (gap) phases, no DNA

is synthesized but RNA, proteins, and other
compounds are synthesized. Cytokines act in
concert at each of these phases to drive the cell
along its cycle, which ends with mitosis or cell
division.
The B lymphocytes have on their cell surfaces immunoglobulins that act as receptors
for the antigen. The binding of the antigen is a
random process. lf an antigen binds tightly
(fits) with the immunoglobulin receptor, then
the activation process starts. The B cell internalizes the antigen and presents it along with
a dass II MHC molecule to the T ce!!. The T
and B lymphocytes then form a tight bond
with each other, a T-B conjugate. The activated T cell secretes cytokines such as IL-2.
Thus, the process of B-cell activation requires
(1) membrane changes that induce secondary
changes within the cytoplasm and nucleus
and (2) the presence of cytokines such as IL-1
and IL-4, in the early and IL-2, IL-4, and IL-5
in the later differentiation events. When a B
lymphocyte becomes fully differentiated, the
antibody is no longer present on the cell surface acting as a receptor but is in the cytoplasm of a plasma cell that is producing large
quantities of a specific antibody. (See Figure
2.6.) The process of clonal selection of responding B cells is the basis of the memory
response to that antigen.

The lmmune System

31

Figure 2.6 Activation of B cells to produce antibody. Receptors on the surface of B cells bind
matching antigen which is then engulfed and processed by the B cell. A piece of the antigen,
bound to a class 11 protein, is then presented on the surface of the B cell. This complex binds to a
mature helper T cell, which releases interleukins that transform B cells into antibody-secreting
plasma cells. When released into the bloodstream, antibodies lock onto matching antigens and are
eliminated by the complement cascade or by the liver and the spleen.
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lmmunoglobulins
Antibodies are proteins whose function it is

to bind the antigen, causing the antigen to
lyse, precipitate out, or be more easily phagocytized. The antigen-antibody complex can
activate the complement system, or prevent
viruses from reacting with receptor sites on
cells. When the chemical nature of these proteins are referred to, they are called immunoglobulins. The five main classes of immunoglobulins are IgG, IgM, IgA, IgD, and IgE.
Immunoglobulins are composed of four
polypeptide chains. Two of the chains are
called the heavy chains and two are called the
light chains. This unit of four is also called a
monomer. Greek letters have been assigned to
the various chains. The light chains are either
kappa (K) or lambda (A) no matter what the
class of the immunoglobulin. The heavy
chains take their name from the immunoglobulin class. The heavy chains for IgG, for
instance, are called gamma ("y), for IgA, alpha
(a), for IgM, mu (¡..¡.). Immunoglobulins are
bifunctional proteins in that one end of the
molecule structure comprises a highly variable region, that is, the amino acid sequence
differs greatly from one antibody to another.
This is the region which binds to or is complementary to the antigen. The other end of the
molecule can bind to membrane receptors and
is known as the constant region, or Fe fragment. Macrophages, killer cells, mast cells,
and placenta! cells all have Fe receptors that
can bind to immunoglobulins. The fragment
that binds to the antigen is composed of one
end of the heavy chain and the light chain.
The Fe fragment consists of the other end of
the heavy chain. Since each monomer of an
immunoglobulin has two heavy and two light
chains, an immunoglobulin can bind two antigenic sites.
Of al! the immunoglobulin classes, IgG is
present in the highest concentration in the
plasma and is responsible for most specific
antibody reactions in the adult. It is the principal antibody secreted in the secondary response and is the antibody passed from the
maternal blood to the fetus that is responsible

for protection of the fetus and newborn. Two
of the four subdasses of IgG are able to activate complement. Also, macrophages and
neutrophils have receptors on their cell surfaces that can bind to IgG.
The antibody IgM is formed first. It is the
first class of immunoglobulins to be formed in
the fetus and the first in primary infections. It
is a large molecule, a pentamer, composed of
five monomer units, that is very efficient in
agglutinating particles such as viruses. Present in mucosa! secretions, breast milk, and
saliva, IgA helps prevent antigens from gaining access to the systemic circulation. It is the
second most abundant immunoglobulin in the
serum (10% to 15%). A fourth immunoglobulin, IgE, is present in allergic reactions such
as asthma and hay fever and in parasitic infections, and is also known as reaginic antibody.
It is present in minute amounts in the plasma,
but in the tissues is bound to the surface of
mast cells. Not much is known about IgD. It is
present in small amounts in the circulation
and is involved in the regulation of immunoglobulin synthesis.
Primary and Secondary Responses

The responses of the immune system are different the first time an antigen is encountered
from those of second or subsequent times. The
first or primary response takes a longer time
to develop and is not as specific nor as sustained as the responses to secondary encounters. Whereas in a primary response IgM is
formed first and IgG later, in the secondary
response IgG titers are much higher than
those generated in the primary response, and
they are sustained for a longer period of time
(Figure 2.7). That is why vaccinations to a
particular microorganism are given severa!
times, to generate clones of lymphocytes that
can respond more quickly to the presence of
an antigen.
Complement

The complement system is a series of about 20
plasma proteins that acts as a bridge between
the specific antibody response and the non-
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Figure 2.7 Primary and secondary immune
responses. Secondary immune responses are
distinguished from primary ones by the
decrease in the latent period, greater specific
and more sustained response.

Primary and secondary
immune responses
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capillary permeability, which causes edema.
These functions are vital to the clearance of
microorganisms from the host. Individuals
who have a congenital deficiency of one of the
complement proteins are at higher-thannormal risk of chronic infections or autoimmune diseases.
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specific inflammatory response. Complement
acts to magnify and expand the specific antibody response. The complement proteins circulate as proenzymes or inactive enzymes.
When the complement cascade is triggered,
often by an antibody-antigen complex, the
proteins become active in a series of enzymatic reactions that resemble the blood clotting
cascade. The end product of both the classical
and the alternative complement pathways is
the membrane attack complex. This complex
inserts a doughnut-shaped channel into the
membrane, which allows lysis of the cell on
which the antibody-antigen complex was
attached.
When the inactive complement proteins
are activated, small polypeptides are released.
These small "split products" are nonspecific
activators of inflammation and act as chemotactic agents, attracting white blood cells to
the area; opsonins, enhancing phagocytosis of
the antigen; and anaphylactoid agents, inducing the release of histamine, and increasing

The T cell is responsible for cell-mediated
immunity, i.e., immunity carried out by cells.
This type of immunity protects the body
against intracellular organisms such as viruses and parasites, and malignant cells. T
cells are also responsible for immunoregulation through secretion of lymphokines. These
responses can be broadly divided into two
types, the cytotoxic response and the Thelper response.
T-Helper Cell Responses

The T-helper (CD4) cell is the primary cell
responsible for initiation of a specific immune
response. Moving a T cell from its resting
phase requires the binding of the T-cell receptor with a processed antigen, which is in
turn bound to a MHC complex; it also requires the presence of various cytokines such
as IL-1. Interleukin- 1 produced by accessory
cells such as macrophages, causes, along with
antigen-MHC stimulation, a change in the
plasma membrane and then an activation of
IL-2 and the IL-2 receptor genes. This production and secretion of IL-2 and its binding
to the IL- 2 é:ell-membrane receptor drives the
T cell through to the S phase of the cell cycle.
The end result is a differentiated T cell that
can produce lymphokines which mediate
T-cell immunity, and activate cytotoxic T
cells, whose function is to directly lyse cells.
The T-helper cell is a majar producer of
lymphokines.
The T-helper response generates a delayed hypersensitivity reaction, the prototype
of which is the positive PPD reaction. The
results of the PPD test are read after 36 to 72
hours, a delayed response that contrasts with
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Figure 2.8 Activation of T cells. After a macrophage internalizes and processes antigen, it presents
antigen fragments on its surface in conjunction with class 11 proteins to the helper T cell. Cytokines
secreted by the macrophage help the T cell to mature. The activated T cell then secretes additional
lymphokines that attract other immune cells to the area, activate cytotoxic T cells, and cause the
growth of more T helper cells.
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the B-cell or immediate hypersensitivity response. A typical immediate hypersensitivity
response is a penicillin reaction. The T-cell
responses control intracellular pathogens such
as Mycobacteria, fungi, and viruses, and eliminate altered and malignant cells. Graft rejection and graft-versus-host disease are also
T-cell responses.
Cytotoxic T-Cell Responses
The cytotoxic T-cell response requires direct
physical contact between the cytotoxic T cell
(CD8 lymphocyte) and the target cell (Figure
2.8). Generally, the CD8 cells are MHC class I
restricted, meaning that the target cells must
have MHC class 1 antigens expressed on their
surfaces. Since almost every cell in the body
expresses MHC class 1 antigens, almost every
cell can be killed by cytotoxic T cells.
Before directed cell k.illing begins, specific
T-helper cells are stimulated by the antigen.
This expanded pool of T-helper cells then produces IL-2. It is in response to both this IL-2
and the antigen presented with the MHC class
I molecule that the resting cytotoxic T cell is
stimulated to proliferate and differentiate. The
killing of the target cell is the result of a series
of steps, starting with the joining or conjugation of the cytotoxic T cell and the target ce!!.
Conjugation is dependent on the binding of
the T-cell receptor-CD3 complex with the
antigen-MHC class I complex on the target
ce!!. A series of membrane changes occur in
the cytotoxic T cell generating a signa! in the
protoplasm. Orientation of the Golgi complexes and granules in the cytotoxic T cell
toward the target cell occurs next, then the
contents of the granules are released in the
space between the cytotoxic T cell and the
target ce!!. The cytotoxic T cell migrates away
and is ready to start the cycle again; shortly
after, the target celllyses. Any one cytotox.ic T
cell can kili multiple target cells and yet not be
harmed itself. The target cell is lysed when
pores or channels form in the target cell membrane in a manner reminiscent of complement
lysis. However, the proteins required for each
type of reaction are different molecules.
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TUMOR IMMUNOLOGY
The first experimental system used to study
tumor biology was the transplantation of tumors between animals. When this work was
started in the late-1800s, inbred strains of animals were unknown, thus, what the scientists
were really studying was allogeneic transplantation and responses to antigens. Around the
same time, Dr. Coley (see Chapter 1) observed
tumor regression in a few patients who had
serious infections. He devised a vaccine that
would simulate a serious infection and tested
it in 1200 patients; 270 of these had complete
regression of tumor. Now we know that responses to infections, tumors, and transplantation are all related and that insights into the
mechanisms of one are relevant to the other
two. The other side of understanding immune
responses to infections and transplantation is
understanding tolerance to self molecules, an
area of study that has helped in discovering
the way tumors can evade recognition and destruction by the immune system.

lmmune Surveillance
and Tumor Antigens
In the 1950s, knowledge of the body' s reaction to tumors was synthesized by MacFarlane Burnett into a theory of a process
termed immune surveillance. Expressed in
somewhat popular terms, the theory states
that (1) all individuals form tumor cells; (2)
not everyone develops a malignancy; and (3)
it is the immune system that prevents the
development of tumors. As stated, the theory
can not be directly tested because it is almost
impossible to prove the negative, an absence
of tumors. However, worded differently, this
theory implies that tumors have antigens that
under appropriate circumstances can be identified by the immune system. In animal
models, the tumor antigens are called tumor
transplantation antigens, reflecting the design
of the experiments to test these ideas. One
way to study tumor rejection and tumorassociated transplantation antigens is to inject
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nonviable tumor cells (obtained from another
animal of the same inbred line) into an animal as a vaccine. When the animal is later
challenged with live tumor cells, it is able to
reject the tumor. ·A control animal without
prior exposure to the tumor cell vaccine is
unable to reject the live tumor cells and develops a malignancy.
Because transplantation experiments with
live tumor cells are not feasible in humans,
tumor antigens are termed tumor-associated
antigens or oncofetal antigens. Very few antigens in humans are associated exclusively
with malignancy. Most antigens are also present in other pathologic states or in the fetus.
Two tumor-associated antigens that are usefui clinically are alpha fetoprotein (AFP) and
carcinoembryonic antigen (CEA) . Carcinoembryonic antigen is expressed in gastrointestinal and breast cancers, AFP in hepatocellular and testicular cancers. Alpha fetoprotein has been used in a few screening

programs for the detection of hepatocellular
tumors, but these two antigens are more frequently used as indicators of disease progression. Following surgery for the cancers mentioned above, the plasma concentration of the
oncofetal antigen usually drops dramatically.
If disease recurs, the levels rise once again. A
rise in CEA levels might be the first indicator
of relapse. However, CEA levels rise in only
60% to 94% of patients, so a negative CEA
report does not guarantee an absence of
metas tases.
Although tumor antigens have been discovered, not all experimentally induced tumors produce antigens recognized by the immune system and sorne evoke only a "weak"
immune response. This is also true of tumors
that arise spontaneously, in animals as well as
in humans. On the surface of any tumor cell,
however, there are many surface marker molecules, such as differentiation antigens, tissuespecific antigens, and receptors, sorne of
which may be exploited for identifying, classifying, and treating the malignancy. Tumorinfiltrating lymphocytes can recognize sorne
tumor-associated antigens.

In the clinic, tumor antigens are detected
by monoclonal antibodies to these antigens.
As noted above, these monoclonal antibodies
can be used in screening and determining
tumor progression. They can also be linked
to special stains and used in the diagnosis of
the tumor type and subtype. For instance,
the CD10 antigen, also known as the commo n acute lymphoblastic leukemia antigen
(CALLA), appears in the leukemic cells of approximately 70% of children diagnosed with
acute lymphocytic leukemia. This antigen is
also seen in Burkitt's and follicular lymphomas. Tumor antigens can also be used to
determine the T- or B-celllineage and the differentiation state of leukemias. Cells positive
for CALLA are of the B-celllineage. Monoclonal antibodies to surface antigens are used to
determine the tissue of origin in undifferentiated or poorly differentiated tumors. Monoclona) antibodies can help distinguish tumors
of epithelial and connective tissue origins. In

clinicaJ trials, monoclonal antibodies are now
being linked with radioactive compounds, traditional chemotherapeutic agents, or toxins to
determine their utility either in imaging oras
therapy. (See Chapter 7.)

Oncogenes, Tumor-Suppressor
Genes, and Tumor Antigens
Cancer is a disease of cell growth and division;
underlying this abnormal cellular state are genetic changes. The genetic changes that arise in
carcinogenesis include point mutation (the
change of one nucleotide base in the gene); gene
amplification, alterations in the gene control
mechanisms; chromosomal deletions and insertions; and chromosomal abnormalities. As the
tumor progresses, more and more genetic
changes accumulate. One of the main functions
of the gene is to code for proteins. Therefore, if
carcinogenesis is initiated with a genetic change
and that change results in an altered protein,
then that protein could be recognized, allowing
diagnosis, and become a target for chemotherapy or biological agents.

The lmmune System

The genes that have been associated with
carcinogenesis are caBed oncogenes. Oncogenes were first recognized in experimental
virology, where it w~as observed that viral
genes could transform cells in culture. When
these genes were placed into cell cultures,
they caused the phenotype of the cell to
change and take on the appearance of a tumor
cell. Since the cells were in a culture, the process was called transformation rather than
carcinogenesis. It was then discovered that
viral oncogenes had a normal cell equivalent,
called proto-oncogenes. lf these genes were
first recognized for their normal function, perhaps then they would be called growth, division, and repair genes instead of oncogenes.
These genes are responsible for controlling the
highly regulated processes of the cell cycle,
that is, the sequencing and coordination of the
cell through the G(}l G 11 S, G 21 and mitosis
phases. The initiating event in cell growth and
division is termed a signa!. The signa!, which
might be a growth factor, hormone, cytokine,
or antigens, initiates a complex series of actions at the surface membrane and in the cytoplasm and nucleus. Proto-oncogenes are involved in coding for the proteins that act as
growth factors, growth factor receptors, and
signaling complexes at the membrane; second
messengers in the cytoplasm; and regulators
of gene expression.
The existence of tumor-suppressor genes
or recessive oncogenes was first hypothesized
from epidemiologic data. Knudson developed
a mathematical model to explain the difference in age of onset of unilateral and bilateral
retinoblastoma. He suggested that individuals
with familia! disease with increased risk for
bilateral disease were born with one defective
gene of the pair of maternal and paternal
genes that control retinoblastoma. (Most
genes in the body, except those on the X and Y
chromosomes in males, occur as pairs.) The
mutation of one allele of the pair of genes
occurs earlier in life in patients with familia!
disease than in those with unilateral disease.
Unilateral disease occurs Jater in life than bilateral disease and requires that mutations oc-
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cur in both the maternal and paternal genes;
since the presence of at least one functioning
gene inhibits the growth of the tumor. Great
progress has been made in identifying the
tumor-suppressor genes in retinoblastoma,
Wilms' tumor, von Recklinghausen' s neurofibromatosis, familia! adenomatous polyposis,
and colorectal carcinomas. These genes have a
variety of actions, including suppression of
cellular transcription factors, DNA replication, and gene transcription.
Clearly, regulation of normal growth and
division is complex and under tight control.
This complexity in itself may Jead to multiple
metabolic errors. There are, however, normal
cellular mechanisms that limit or correct for
these errors. Oncogene products, growth factors, and growth factor receptors are alllinked
in this complex regulatory system. In malignant diseases, sorne of the oncogenes are
structurally different from their proto-oncogene counterparts. Other oncogenes are expressed in higher amounts in cancer cells than
in normal cells, and tumor-suppressor genes
may be entirely lack.ing in the tumor cells. In
the future, the protein products of oncogenes
might be targets of immunotherapies such as
antibodies directed to growth factor receptor
produced by an oncogene; the manufacture of
suppressor gene products may lead to the development of new biological agents. (See
Chapter 16.)

lmmune Responses to Tumors
There is sorne evidence that almost every immune response that has been identified, including cellular and antibody-mediated immunity, is also generated as a response to
tumor cells. Probably the most protective responses to tumors are cellular responses,
which are similar to those generated against
viruses. The important cells in these reactions
are cytotoxic T cells, macrophages, NK cells,
and antibody-dependent cytotoxic cells. Since
the biology of the tumor changes with tumor
progression, it may be that the relative importance of one type of immune response differs
at the various tumor stages.
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Sorne lines of evidence for an immune
response to tumors come from the study of
histopathology. To establish a diagnosis of
cancer in humans, biopsied tissue is sent to
the pathology lab9ratory, where it is stained
and examined. Sorne tumors have marked
infiltrates, often called a mononudear infiltrate (lymphocytes and macrophages), which
suggests that the tumor has stimulated an
immune response in the individual. In sorne
instances (medullary carcinoma of the breast,
for example) the presence of a mononuclear
infiltrate means a more favorable prognosis
for the patient. Other clinical signs that have
suggested an immune response to tumors is
the waxing and waning of tumors. In such
cancers as melanomas, the lesions are visible.
Sorne of the lesions will disappear from one
area and other tumor deposits will appear
simultaneously at distant sites. lt has been
suggested that the reason for tumor fluctuations is that the immune responses were able
to eliminate the tumor from one small area
but not to control the progression of the disease in other areas. Spontaneous regression of
a diagnosed malignancy is an extremely rare
event, but there have been reports of regression in carcinoma of the kidney, neuroblastoma, choriocarcinoma, and melanoma.
Again, immune mechanisms appeared to offer
the best explanation for the regression. Although clinica1 evidence suggests the existence of immune responses to tumors, it does
not constitute definitive proof. Animal experiments provide further evidence for immune
responsiveness to tumors; the development of
a cancer-preventing vaccine would be a
definitive proof of the theory of immune
surveillance.
Ceii-Mediated Cytotoxicity
Cytotoxic T cells can recognize and destroy
malignant cells by the same mechanisms they
use to recognize and destroy cells infected
with viruses. The cytotoxic T-cell receptor attaches to the tumor antigen, which is complexed with the class I MHC antigens. The

direct contact and binding results in the release of enzymes and lysis of the tumor cell
within a few minutes. As with many other
specific cytotoxic T-cell reactions, T-helper cell
activation is necessary. The T-helper cells are
al so activated by the presentation of the tumor
antigens linked to MHC on macrophages, and
activation of T-helper cells can also result in
nonspecific cytotoxicity. These cells release
lymphokines, which activate macrophages in
the area of the tumor. The activated macrophages release lytic enzymes, proteases, and
reactive oxygen intermediates which destroy
the tumor cells. ln another type of cytotoxicity, antibody-dependent cytotoxicity, antibodies bound to a cytotoxic cell, either an NK
cell or a macrophage, cross-link the cytotoxic
and tumor cells. This binding creates changes
in the cell membrane of the macrophage, causing release of lytic granules and death of the
tumor cell. Natural killer cells are also responsible for the killing of tumor cells but,
unlike the cytotoxic T cells, NK cells do not
need prior exposure to generate a cytotoxic
response to the tumor cell.
Antitumor Antibodies
In animal experiments, the injection of tumor
cells has resulted in the production of antitumor antibodies. The binding of these antibodies to macrophages can lead to tumor cell
lysis as described above in antibody-dependent cytotoxicity. Antitumor antibodies could
also act as an opsonin. The binding of antibodies to the surface of tumor cells allows
phagocytosis by macrophages to occur more
readily. Binding of antibodies may also result
in the activation of the complement system
and the destruction of the tumor ce!!. Paradoxically, in sorne animal models it has been
shown that the production of antibodies to
tumors interfered with cell-mediated antitumor immune responses. Many of the studies
in humans of antitumor antibodies have been
conducted in patients with melanoma. Very
few of these patients, about 6%, generate antitumor antibodies.

The lmmune System

Cytokines

Cytokines are low-molecular-weight regulatory proteins produced by various cells. If
these proteins are propuced by lymphocytes,
they are called lymphokines; if by monocytes,
they are referred to as monokines. Several
cytokines are k.nown to have an antitumor
effect; they may act alone or in concert with
other cytokines. Interferons, tumor necrosis
factors, and interleukin-2 are sorne of the
more well-k.nown cytokines with cytotoxic or
antiproliferative effects. For instance, interferon gamma activates NK cells, thereby increasing NK cytotoxicity. The interferons are
antiproliferative agents and can increase the
expression of MHC antigens, which are necessary for T-cell activation. Tumor necrosis factors are secreted by macrophages, NK cells,
and T-helper cells. They can directly lyse
tumor cells and act in a synergistic fashion
with interferon. The cloning of the genes for
cytokines and their commercial production
has led to an explosion of knowledge about
these powerful cell regulators and to their exploitation for therapeutic purposes.

Tumor Escape Mechanisms
Obviously, when a patient is diagnosed with
a malignancy, whatever antitumor immune
mechanisms were present were not effective.
Severa! different mechanisms are k.nown by
which tumors apparently evade the immune
system. Antigenic modulation, one of the escape mechanisms, is readily observed in animal models. For instance, an animal that is
immunized to a tumor may produce antibodies to the tumor antigen. The antibodies
form complexes with the tumor antigen and
are taken into the cell by endocytosis or shed to
the environment. As long as the antibodies are
present, the antigen is lost from the tumor surface and cannot be recognized by a cytotoxic T
cell-killing is prevented. Alternatively, shedding of tumor antigens or tumor antigenantibody complexes may block the activity of
the cytotoxic cells.
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In humans, as the tumor progresses, it
may be that the tumor cells that are most
easily recognized by the immune system are
killed. Those tumor cells that are left may not
express the tumor cell antigen and are able to
proliferate without stimulating an immune
response. Tumor ce lis may be able to " sneak
through" the immune surveillance network.
According to this theory, so few cells and
tumor antigens are present early in the
growth of a tumor, that the immune system
is not stimulated. Later in the natural history
of the tumor, there is a sufficient amount
of tumor antigen present to stimulate the
immune system, but by then the tumor is too
large to be controlled by the immune response.
Cell-adhesion molecules are expressed on
most somatic cells in the body. These molecules are necessary for the adherence of cytotoxic cells to a target cell befare lysis can
ensue. During the natural history of tumors,
there are multiple genetic changes that are
reflected in the phenotype of the cell. One of
the changes that occurs in tumor cells is the
loss of these cell-adhesion molecules. With
the loss of these molecules, cytotoxic cells
cannot bind as tightly to the malignant cells
and thus the tumor can escape immune
surveillance.
Class 1 MHC molecules on the target cell
and the presence of antigen are necessary for
cytotoxic T-cell killing. Transformation of
cells to a malignant phenotype occurs along
with the loss or a decrease in the expression
of class 1 MHC molecules. Theoretically, the
loss of these molecules may allow the tumor
cell to escape recognition by the cytotoxic
cell.
Besides these mechanisms, tumor cells
may produce factors that inhibit immune responsiveness. For instance, tumor cells may
secrete prostaglandins, which inhibit inflammation and block synthesis of chemotactic
factors. This would limit the number of lymphocytes and monocytes in the area of the
tumor.
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AUTOIMMUNE DISEASES
Autoimmune diseases are another group of
diseases in which biological therapies hold
great promise. When the immune system reacts against self antigens, the ensuing state is
called autoimmurtity. Approximately 6% of
the population suffer a chronic debilitating
autoimmune disease. Autoimmune diseases
are classified as (1) organ-specific diseases
such as Addison's disease, Graves' disease,
myasthenia gravis, and poststreptococcal
glomerulonephritis or (2) systemic diseases
such as ankylosing spondylitis, multiple sclerosis, rheumatoid arthritis, and systemic
lupus erythematosus. The current therapies
for autoimmune diseases are mainly those of
nonspecific immunosuppression, including
pharmacological agents such as steroids and
cyclosporine, plasmapheresis, lymph node irradiation, and thymectomy. lt has been suggested that more specific biological therapies
will become available for these diseases in the
future that will have fewer side effects than
present therapies and will be directed at the
immunological abnormalities.
Autoimmunity is the loss of self tolerance.
Normally, lymphocytes that recognize self antigens are eliminated, usually in the fetus, in a
process called clona! deletion. Most adults
have clona} anergy, that is, lymphocytes that
can react against self molecules are present in
the circulation but do not react. This state of
self tolerance must be maintained through
regulation of immune responses. As discussed
earlier, T-helper cells, T-suppressor cells, the
interactions of the MHC antigens and T-cell
receptors, and the cytokines are all responsible for regulatory reactions.
All these reactions are currently being
studied to determine their role in autoimmune
diseases. A great deal of research is now being
done to determine the roles of MHC antigens
and T-cell receptors in autoimmune diseases.
1t appears that many autoimmune diseases
are associated with MHC class 11 genes and
may result from the inappropriate expression
of MHC antigens on cells in the target tissue.
The relative risk of developing an autoim-

mune disease is high for individuals who possess certain MHC alleles. Individuals with the
HLA-827 allele, for instance, have a 90% risk
of developing ankylosing spondylitis, and
those with the HLA-DR3/ DQW8 allele have a
100% risk of developing insulin-dependent diabetes. The exact mechanisms of the pathogenesis of these diseases are being explored in
animal models, along with specific therapies
directed at the T-helper cell receptors and specific T-cell clones. Autoimmune reactions may
involve the B-cell system with the production
of autoantibodies, the T-cell system with the
inappropriate activation of cytotoxic T cells or
T-helper cells, or both T-cell and B-cell immune responses.
Current experimental approaches to autoimmune diseases in animal models include
the administration of monoclonal antibodies
(Kuby, 1992; Wolsy, 1988). In mice with an
autoimmune lupus-like syndrome, treatment
with monoclonal antibodies to the CD4 molecule (T-helper cell) and to the IL- 2 receptor
has led to recovery and relief of symptoms.
The administration of anti-CD4 antibodies
prevented the lymphocytic infiltration of the
pancreas and the relief of diabetic symptoms
in another experimental animal model (Waldmann, 1988). Monoclonal antibodies to MHC
molecules prevented the development of experimentally induced multiple sclerosis.
Many strategies other than monoclonal antibody therapies are also being studied for their
ability to modify the inflammatory and immune responses responsible for autoimmune
diseases, rejections of transplants, and hypersensitivity states.

SUMMARY
The immune system serves as the body' s defense system through the functions of protection from pathogenic organisms, surveillance,
and homeostasis. Immune responses are divided into two types-innate and adaptive
immunity. lnnate or nonspecific defenses involve such mechanisms as intact skin and mucous membranes, the acidic environment of
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the stomach, the cleansing effect of tears, saliva, exfoliation of the skin, and the inflammatory response. These defenses form the body's
first line of defense ag,ainst pathogens. White
blood cells, neutrophils, basophils, and eosinophils are important primarily in nonspecific defenses.
If innate immunity fails, adaptive immunity is enlisted. Specific immune responses
recognize foreign antigens while tolerating self
molecules. The hallmarks of adaptive immunity are memory and specificity. A additional
property of specific immune responses is their
ability to react in a more specific and sustained
fashion upon the second and subsequent encounters with the antigen. Lymphocytes and
macrophages are primarily involved in specific immune reactions. Lymphocytes can be
classified as B cells responsible for the production of antibodies (immunoglobulins); T
cells are important in cytotoxic and regulatory
reactions.
The immunoglobulin receptor on the B
cell and the T-cell receptor are responsible for
the specific recognition of the antigen. The
major histocompatibility genes control interactions among cells of the immune system.
These genes code for molecules (MHC antigens) on cell surfaces that are recognized by
T lymphocytes which require the antigen to
be complexed to self MHC antigens for recognition. Cytokines are powerful mediators
released during inflammatory and immune
reactions. Although separate, there is significant interaction between innate and adaptive
immunity and both are typically required to
effect a sufficient response to eliminate
pathogens.
The theory of immune surveillance implies that the immune system is capable of
recognizing and destroying tumors. When a
tumor is diagnosed in a patient, theoretically
that tumor has evaded or sneaked through the
immune surveillance system. Under appropriate conditions the immune system can recognize tumor associated antigens. T-cell responses to tumor cells resembles immune
responses to viruses. B-cell responses to tu-
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mors also occur. Both activated macrophages
and natural killer cells can lyse tumor cells,
natural killer cells without prior exposure.
Rapid advances in technology such as genetic engineering and recombinant DNA technology, coupled with a more complete understanding of the immune response and the
molecular basis of oncogenesis have led to the
utilization of biological proteins in the treatment of cancer. Numerous cytokines; interferons, interleukins, hematopoietic growth
factors, tumor necrosis factor and monoclonal
antibodies, are now in clinical investigation or
have received regulatory approval. As research continues to progress, new avenues of
treatment will become available.
Oncogenes when functioning normally
regulate cellular growth, division and differentiation. Suppressor genes or recessive oncogenes inhibit the development of the malignant phenotype in a cell. In the future, protein
products of oncogenes or suppressor gene
products may be used as biological therapy.
Autoimmune states (glomerulonephritis,
systemic lupus, arthritis) are currently being
investigated as to the underlying immunologic abnormalities. In the future, biologicals may also be manufactured that will control these illnesses.
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